Homrich & Berg grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.8% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 68,186 shares of the company’s stock after acquiring an additional 4,367 shares during the quarter. Homrich & Berg’s holdings in Johnson & Johnson were worth $11,206,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $4,370,566,000. Arrowstreet Capital Limited Partnership boosted its position in shares of Johnson & Johnson by 42.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 9,004,994 shares of the company’s stock valued at $1,479,971,000 after purchasing an additional 2,688,957 shares in the last quarter. Sanders Capital LLC boosted its position in shares of Johnson & Johnson by 28.1% during the first quarter. Sanders Capital LLC now owns 8,441,664 shares of the company’s stock valued at $1,543,394,000 after purchasing an additional 1,851,609 shares in the last quarter. Morgan Stanley boosted its position in shares of Johnson & Johnson by 7.3% during the fourth quarter. Morgan Stanley now owns 24,111,028 shares of the company’s stock valued at $3,794,594,000 after purchasing an additional 1,638,263 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of Johnson & Johnson by 0.7% during the first quarter. BlackRock Inc. now owns 189,690,998 shares of the company’s stock valued at $31,175,717,000 after purchasing an additional 1,379,656 shares in the last quarter. 66.60% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson stock traded up $0.69 during mid-day trading on Thursday, reaching $170.18. 113,242 shares of the stock traded hands, compared to its average volume of 6,223,537. The firm has a market capitalization of $448.15 billion, a PE ratio of 29.95, a PEG ratio of 2.71 and a beta of 0.71. The company has a quick ratio of 1.04, a current ratio of 1.28 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12-month low of $133.65 and a 12-month high of $173.65. The firm’s 50-day simple moving average is $167.25.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 7th. Shareholders of record on Tuesday, August 24th will be given a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date of this dividend is Monday, August 23rd. Johnson & Johnson’s payout ratio is 52.80%.
Several research firms have commented on JNJ. Morgan Stanley began coverage on Johnson & Johnson in a report on Friday, May 28th. They issued an “overweight” rating and a $187.00 target price on the stock. Credit Suisse Group set a $193.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, June 7th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $190.38.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also: EV Stocks
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.